Leukotriene B4 levels in CHD-associated paediatric pulmonary hypertension
- 6 March 2024
- journal article
- research article
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (7) , 1471-1475
Abstract
Background: The aim of this study is to evaluate the role of leukotriene B4, an inflammatory mediator, in the development of pulmonary hypertension in paediatric patients with CHD with left-right shunt.Methods: The study included forty patients with CHD with left-right shunts. Based on haemodynamic data obtained from cardiac diagnostic catheterisation, 25 patients who met the criteria for pulmonary arterial hypertension were included in the patient group. The control group comprised 15 patients who did not meet the criteria. The standard cardiac haemodynamic study was conducted. Leukotriene B4 levels were assessed in blood samples taken from both pulmonary arteries and peripheral veins.Results: The median age of patients with pulmonary arterial hypertension was 10 months (range: 3–168), while the median age of the control group was 50 months (range: 3–194). In the pulmonary hypertension group, the median pulmonary artery systolic/diastolic/mean pressures were 38/18/24 mmHg, compared to 26/10/18 mmHg in the control group. Leukotriene B4 levels in pulmonary artery blood samples were significantly higher in the pulmonary arterial hypertension group compared to the controls (p < 0.05). Peripheral leukotriene B4 levels were also elevated in the pulmonary arterial hypertension group in comparison to the control group, though the difference was not statistically significant.Conclusion: The discovery of elevated leukotriene B4 levels in pulmonary artery samples from paediatric patients with pulmonary arterial hypertension secondary to CHD with left-to-right shunt suggests that local inflammation may have a pathological role in the development of pulmonary arterial hypertension.Keywords
This publication has 31 references indexed in Scilit:
- Inflammatory markers in Eisenmenger syndrome and their association with clinical outcomes. A cross-sectional comparative studyInternational Journal of Cardiology, 2021
- Imbalanced serum levels of resolvin E1 (RvE1) and leukotriene B4 (LTB4) in patients with allergic rhinitisMolecular Biology Reports, 2020
- Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectatorCardiovascular Research, 2019
- Leukotrienes in pulmonary arterial hypertensionImmunologic Research, 2014
- Blocking Macrophage Leukotriene B 4 Prevents Endothelial Injury and Reverses Pulmonary HypertensionScience Translational Medicine, 2013
- Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial HypertensionComprehensive Physiology, 2011
- Reversed changes of lipoxin A4 and leukotrienes in children with asthma in different severity degreePediatric Pulmonology, 2010
- LeukotrienesNew England Journal of Medicine, 2007
- 5-Lipoxygenase and FLAPProstaglandins, Leukotrienes and Essential Fatty Acids, 2003
- Metabolic disposition of leukotriene B4 (LTB4) and oxidation‐resistant analogues of LTB4 in conscious rabbitsBritish Journal of Pharmacology, 1994